Cargando…
Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity
[Image: see text] The use of the tumor suppressor p53 for gene therapy of cancer is limited by the dominant negative inactivating effect of mutant endogenous p53 in cancer cells. We have shown previously that swapping the tetramerization domain (TD) of p53 with the coiled-coil (CC) from Bcr allows f...
Autores principales: | Okal, Abood, Cornillie, Sean, Matissek, Stephan J., Matissek, Karina J., Cheatham, Thomas E., Lim, Carol S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114475/ https://www.ncbi.nlm.nih.gov/pubmed/24836513 http://dx.doi.org/10.1021/mp500202p |
Ejemplares similares
-
Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model
por: Okal, Abood, et al.
Publicado: (2014) -
High performance liquid chromatography in food control and research /
por: Matissek, Reinhard
Publicado: (1993) -
Análisis de los alimentos : fundamentos, métodos, aplicaciones
por: Matissek, Reinhard
Publicado: (1998) -
GPCR homo-oligomerization
por: Milligan, Graeme, et al.
Publicado: (2019) -
GLI3: a mediator of genetic diseases, development and cancer
por: Matissek, Stephan J., et al.
Publicado: (2020)